Welcome to our Clinic
The data presented in the Canada Vigilance Adverse Reaction Online Database has been updated and now includes information received by Health Canada up to September 30, 2025. The next update of data is scheduled for early February, 2026.
Closing the knowledge gap: identifying research priorities for firearm-related injury and mortality in Canada; Identifying social prescribing core outcomes using a Delphi approach: findings and future directions
The list of new safety and effectiveness reviews has been updated and now includes safety reviews initiated between November 1 and 30, 2025. The next update is scheduled for February 2026.
Content: Safety brief: Bruton’s tyrosine kinase (BTK) inhibitors and the risk of serious hepatotoxicity; Notice of authorization with conditions: Lyvdelzi (seladelpar)
The list of new safety and effectiveness reviews has been updated and now includes safety reviews initiated between October 1 and 31, 2025. The next update is scheduled for January 2026.
The data presented in the Canada Vigilance Adverse Reaction Online Database has been updated and now includes information received by Health Canada up to August 31, 2025. The next update of data is scheduled for early January, 2026.
Content: Product monograph update: Braftovi (encorafenib); Notice of authorization with conditions: Jaypirca (pirtobrutinib); Notice of authorization with conditions: Leqembi (lecanemab)
The data presented in the Canada Vigilance Adverse Reaction Online Database has been updated and now includes information received by Health Canada up to July 31, 2025. The next update of data is scheduled for early December, 2025.
The list of new safety and effectiveness reviews has been updated and now includes safety reviews initiated between September 1 and 30, 2025. The next update is scheduled for December 2025.
Content: Announcement: Distribution of the reserve list for antimicrobial drugs via the Canadian Clinical Drug Data Set; Safety Brief: Change in the colour from teal to red for the ferrule / cap of marketed cisatracurium besylate injectable products; Notice of authorization with conditions: Amtagvi